Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.65 |
| ▸ | EML4 | Q9HC35 | 7/20 | 0.65 |
| ▸ | INSR | P06213 | 2/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.63 |
| ▸ | ROS1 | P08922 | 1/20 | 0.63 |
| ▸ | FER | P16591 | 1/20 | 0.63 |
| ▸ | LTK | P29376 | 1/20 | 0.63 |
| ▸ | BLK | P51451 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.63 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19089369 | 0.93 | EGFR (0.73) | EGFRALKEML4PTK2KCNH2 | |
| SCHEMBL35210286 | 0.91 | EGFR (0.61) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL20548806 | 0.91 | EGFR (0.61) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL30775467 | 0.87 | EGFR (0.60) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL22495028 | 0.87 | EGFR (0.60) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL19089589 | 0.87 | EGFR (0.62) | EGFRALKEML4IGF1RKCNH2 | |
| SCHEMBL20548920 | 0.87 | EGFR (0.68) | EGFRALKEML4KCNH2 | |
| SCHEMBL19089586 | 0.87 | EGFR (0.64) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL35210325 | 0.87 | EGFR (0.64) | EGFRALKEML4INSRERBB2 | |
| SCHEMBL22415729 | 0.84 | EGFR (0.65) | EGFRALKEML4INSRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | claimed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| CN-106928150-B | Acrylamide aniline derivative and pharmaceutical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ALK 54/4885EML4 1799/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ALK 54/4885EML4 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.